📣 VC round data is live. Check it out!

Personalis Valuation Multiples

Discover revenue and EBITDA valuation multiples for Personalis and similar public comparables like Abclon, Eikon Therapeutics, ToolGen, CryoPort and more.

Personalis Overview

About Personalis

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.


Founded

2011

HQ

United States

Employees

229

Financials (LTM)

Revenue: $73M
EBITDA: ($86M)

EV

$418M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Personalis Financials

Personalis reported last 12-month revenue of $73M and negative EBITDA of ($86M).

In the same LTM period, Personalis generated $15M in gross profit, ($86M) in EBITDA losses, and had net loss of ($89M).

Revenue (LTM)


Personalis P&L

In the most recent fiscal year, Personalis reported revenue of $70M and EBITDA of ($71M).

Personalis is unprofitable as of last fiscal year, with gross margin of 23%, EBITDA margin of (102%), and net margin of (117%).

See analyst estimates for Personalis
LTMLast FY202320242025202620272028
Revenue$73M$70M$73M$85M$70M
Gross Profit$15M$16M$18M$27M$16M
Gross Margin20%23%25%32%23%
EBITDA($86M)($71M)($97M)($70M)($71M)
EBITDA Margin(118%)(102%)(132%)(83%)(102%)
EBIT Margin(132%)(126%)(131%)(81%)(126%)
Net Profit($89M)($81M)($108M)($81M)($81M)
Net Margin(123%)(117%)(147%)(96%)(117%)

Financial data powered by Morningstar, Inc.

Personalis Stock Performance

Personalis has current market cap of $618M, and enterprise value of $418M.

Market Cap Evolution


Personalis' stock price is $5.90.

Personalis share price increased by 7.2% in the last 30 days, and by 27.4% in the last year.

Personalis has an EPS (earnings per share) of $-0.78.

See more trading valuation data for Personalis
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$418M$618M2.1%7.2%-34.9%27.4%$-0.78

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Personalis Valuation Multiples

Personalis trades at 5.7x EV/Revenue multiple, and (4.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for Personalis

EV / Revenue (LTM)


Personalis Financial Valuation Multiples

As of May 5, 2026, Personalis has market cap of $618M and EV of $418M.

Personalis has a P/E ratio of (6.9x).

LTMLast FY202320242025202620272028
EV/Revenue5.7x6.0x5.7x4.9x6.0x
EV/EBITDA(4.8x)(5.9x)(4.3x)(5.9x)(5.9x)
EV/EBIT(4.4x)(4.7x)(4.3x)(6.1x)(4.7x)
EV/Gross Profit28.1x26.5x22.9x15.6x26.5x
P/E(6.9x)(7.6x)(5.7x)(7.6x)(7.6x)
EV/FCF—(5.3x)(6.2x)(8.9x)(5.3x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Personalis Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Personalis Margins & Growth Rates

In the most recent fiscal year, Personalis reported gross margin of 23%, EBITDA margin of (102%), and net margin of (117%).

See estimated margins and future growth rates for Personalis

Personalis Margins

Last FY20242025202720282029
Gross Margin23%32%23%
EBITDA Margin(102%)(83%)(102%)
EBIT Margin(126%)(81%)(126%)
Net Margin(117%)(96%)(117%)
FCF Margin(114%)(55%)(114%)

Personalis Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth15%(18%)
Gross Profit Growth47%(41%)
EBITDA Growth(27%)1%
EBIT Growth(29%)29%
Net Profit Growth(25%)(0%)
FCF Growth(30%)70%

Data powered by FactSet, Inc. and Morningstar, Inc.

Personalis Operational KPIs

Personalis' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.5M for the same period.

Access forward-looking KPIs for Personalis
LTMLast FY202320242025202620272028
Rule of 40(95%)————
Bessemer Rule of X(59%)————
Revenue per Employee—$0.3M———
Opex per Employee—$0.5M———
R&D Expenses to Revenue72%72%88%58%72%
Opex to Revenue—149%156%112%149%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Personalis Competitors

Personalis competitors include Abclon, Eikon Therapeutics, ToolGen, CryoPort, Pacific Biosciences, Genfit, Mirxes Holding, Myriad Genetics, Castle Biosciences and OPKO Health.

Most Personalis public comparables operate across Diagnostics & Genomics, Life Sciences Tools, BioTech, DeepTech and Longevity.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Abclon183.4x—(52.9x)—
Eikon Therapeutics——(1.6x)(1.4x)
ToolGen595.8x—(23.0x)—
CryoPort2.1x2.1x(178.7x)(95.8x)
Pacific Biosciences5.7x5.5x(5.9x)(6.4x)
Genfit7.0x6.5x(5.5x)(24.6x)
Mirxes Holding19.4x—(5.6x)—
Myriad Genetics0.6x0.6x(1.6x)13.7x

This data is available for Pro users. Sign up to see all Personalis competitors and their valuation data.

Start Free Trial

Personalis Funding History

Before going public, Personalis raised $55M in total equity funding, across 2 rounds.


Personalis Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jan-15Series CAbingworth; Lightspeed Venture Partners; Mohr Davidow Ventures; Stanford University$33M—Personalis is a genomics-based clinical diagnostic laboratory founded in 2011 and spun out from Stanford University. The company developed an Accuracy and Content Enhanced (Ace) technology platform enabling genome sequencing and analytics for personalized cancer vaccines, immunotherapies, and inherited genetic disease diagnosis. Co-founders include CEO John West (former CEO of ViaCyte), Stanford professors Euan Ashley, Russ Altman, and Michael Snyder, and UC San Francisco's Atul Butte. On January 13, 2015, Personalis closed a $33 million Series C financing round led by Lightspeed Venture Partners, bringing total venture capital raised to $75 million. All Series A investors also participated in Series C, including Abingworth and Mohr Davidow Ventures. According to CEO John West, the company had received positive customer responses to its cancer genomics offerings, particularly from pharmaceutical customers, with orders from eleven different countries including five in Asia, and strong repeat business demonstrating customer retention. The company's clinical laboratory was CLIA licensed and CAP accredited. The funding was designated for scaling operations, expanding infrastructure and facilities, recruiting staff, and supporting sales and marketing efforts as the company expanded its product portfolio and customer base.
Oct-13Series BAbingworth; Lightspeed Venture Partners; Mohr Davidow Ventures$22M——

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Personalis

When was Personalis founded?Personalis was founded in 2011.
Where is Personalis headquartered?Personalis is headquartered in United States.
How many employees does Personalis have?As of today, Personalis has over 229 employees.
Who is the CEO of Personalis?Personalis' CEO is Christopher Hall.
Is Personalis publicly listed?Yes, Personalis is a public company listed on Nasdaq.
What is the stock symbol of Personalis?Personalis trades under PSNL ticker.
When did Personalis go public?Personalis went public in 2019.
Who are competitors of Personalis?Personalis main competitors include Abclon, Eikon Therapeutics, ToolGen, CryoPort, Pacific Biosciences, Genfit, Mirxes Holding, Myriad Genetics, Castle Biosciences, OPKO Health.
What is the current market cap of Personalis?Personalis' current market cap is $618M.
What is the current revenue of Personalis?Personalis' last 12 months revenue is $73M.
What is the current revenue growth of Personalis?Personalis revenue growth (NTM/LTM) is 24%.
What is the current EV/Revenue multiple of Personalis?Current revenue multiple of Personalis is 5.7x.
Is Personalis profitable?No, Personalis is not profitable.
What is the current EBITDA of Personalis?Personalis has negative EBITDA and is not profitable.
What is Personalis' EBITDA margin?Personalis' last 12 months EBITDA margin is (118%).
What is the current EV/EBITDA multiple of Personalis?Current EBITDA multiple of Personalis is (4.8x).
How many companies Personalis has acquired to date?Personalis hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Personalis has invested to date?Personalis hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Personalis

Lists including Personalis

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial